Skip to Content
Merck
CN

SML0437

Sigma-Aldrich

Oxandrolone

≥98% (HPLC)

Synonym(s):

17β-Hydroxy-17α-methyl-2-oxa-5α-androstan-3-one, 8075CB, NSC 67068, Oxandren, Provitar, SC 11585, Vasorome

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H30O3
CAS Number:
53-39-4
Molecular Weight:
306.44
EC Number:
200-172-9
MDL number:
MFCD00198944
UNSPSC Code:
51111800
PubChem Substance ID:
329824720
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -19 to -26°, c = 1 (CDCl3)

drug control

USDEA Schedule IIIN; regulated under CDSA - not available from Sigma-Aldrich Canada

color

white to beige

solubility

DMSO: 2 mg/mL (clear solution; warmed)

storage temp.

2-8°C

SMILES string

C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1

InChI key

QSLJIVKCVHQPLV-PEMPUTJUSA-N

Gene Information

human ... AR(367)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Oxandrolone is a synthetic anabolic steroid. It is is a non-aromatizable androgen with no estrogenic effects and with mild androgenic activity. Clinical uses of oxandrolone include to promote weight gain after weight loss following extensive surgery or chronic infections or trauma, to offset the protein catabolism associated with prolonged administration of corticosteroids, to relieve bone pain frequently accompanying osteoporosis, and to treat Turner′s syndrome in girls.
Oxandrolone is an anabolic steroid.

Features and Benefits

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H351,H360FD

Hazard Classifications

Carc. 2 - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SLBJ0457V
035M4743V
082M4703V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rhonda Orr et al.
Drugs, 64(7), 725-750 (2004-03-18)
There has been increasing interest in the development of effective agents that can be safely used to promote anabolism in the clinical setting for patients with chronic wasting conditions as well as in the prevention and treatment of frailty associated
Kim Freriks et al.
European journal of endocrinology, 168(1), 91-99 (2012-10-19)
Short stature is a prominent feature of Turner syndrome (TS), which is partially overcome by GH treatment. We have previously reported the results of a trial on the effect of oxandrolone (Ox) in girls with TS. Ox in a dose
Clinical practice. Short stature in childhood--challenges and choices.
David B Allen et al.
The New England journal of medicine, 368(13), 1220-1228 (2013-03-29)
Gerd G Gauglitz et al.
Current opinion in clinical nutrition and metabolic care, 14(2), 176-181 (2010-12-16)
The hypermetabolic response in critically ill patients is characterized by hyperdynamic circulatory, physiologic, catabolic and immune system responses. Failure to satisfy overwhelming energy and protein requirements after, and during critical illness, results in multiorgan dysfunction, increased susceptibility to infection, and
Emma Jane Gault et al.
BMJ (Clinical research ed.), 342, d1980-d1980 (2011-04-16)
To examine the effect of oxandrolone and the timing of pubertal induction on final height in girls with Turner's syndrome receiving a standard dose of growth hormone. Randomised, double blind, placebo controlled trial. Setting 36 paediatric endocrinology departments in UK
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service